Lyell Immunopharma (LYEL) Operating Leases (2020 - 2026)
Lyell Immunopharma (LYEL) posted Operating Leases of $39.5 million for Q1 2026, down 5.81% sequentially from $41.9 million in Q4 2025, and down 30.83% YoY from $57.1 million in Q1 2025.
Lyell Immunopharma (LYEL) Operating Leases (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Operating Leases for 7 years, with the latest figure at $39.5 million in Q1 2026.
- Quarterly Operating Leases fell 30.83% year-over-year to $39.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.5 million (down 30.83% YoY) and the FY2025 annual result came in at $41.9 million, down 17.79% from the prior year.
- Operating Leases eased to $39.5 million in Q1 2026 per LYEL's latest filing, from $41.9 million in the prior quarter.
- Over five years, Operating Leases peaked at $68.8 million in Q1 2022 and troughed at $39.5 million in Q1 2026.
- A 5-year average of $58.2 million and a median of $58.6 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2026: Operating Leases grew 9.84% in 2022, then sank 30.83% in 2026.
- Over 5 years, Operating Leases stood at $63.2 million in 2022, then declined by 9.93% to $56.9 million in 2023, then declined by 10.37% to $51.0 million in 2024, then declined by 17.79% to $41.9 million in 2025, then dropped by 5.81% to $39.5 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $39.5 million, $41.9 million, and $53.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.60 Mn |
| Mar 31, 2026 | 39.49 Mn |
| Dec 31, 2025 | 41.92 Mn |
| Sep 30, 2025 | 53.07 Mn |
| Jun 30, 2025 | 55.11 Mn |
| Mar 31, 2025 | 57.09 Mn |
| Dec 31, 2024 | 50.99 Mn |
| Sep 30, 2024 | 58.58 Mn |
| Jun 30, 2024 | 60.22 Mn |
| Mar 31, 2024 | 55.16 Mn |
| Dec 31, 2023 | 56.89 Mn |
| Sep 30, 2023 | 64.64 Mn |
| Jun 30, 2023 | 66.07 Mn |
| Mar 31, 2023 | 66.64 Mn |
| Dec 31, 2022 | 63.17 Mn |
| Sep 30, 2022 | 64.64 Mn |
| Jun 30, 2022 | 67.55 Mn |
| Mar 31, 2022 | 68.81 Mn |
| Dec 31, 2021 | 66.65 Mn |
| Sep 30, 2021 | 65.68 Mn |